Core Insights - KellyOCG + Sevenstep has been recognized as a top provider in HRO Today's 2025 Baker's Dozen Customer Satisfaction Ratings for Recruitment Process Outsourcing (RPO), ranking No. 1 in deal size, No. 2 in healthcare and breadth of service, No. 4 in quality of service, and No. 3 overall out of 58 evaluated providers [1][2] Company Performance - The Baker's Dozen list is based on customer feedback from 335 client companies, providing an objective assessment of RPO providers based on service breadth, deal size, service quality, and overall customer satisfaction [2] - The integrated KellyOCG + Sevenstep brand received its first recognition this year, although its individual RPO solutions have been acknowledged for over a decade [3] Technology and Services - KellyOCG + Sevenstep utilizes agile and AI-enabled solutions for talent acquisition, integrating data and predictive analytics to enhance decision-making and strategy effectiveness [3] - The company offers modular and enterprise RPO services, total talent solutions, and industry-leading consulting services, supported by proprietary technology like SevayoInsights [3][4] Industry Position - The company has expanded its global footprint and resources, making it a compelling choice for global enterprise RPO programs and tailored solutions [4] - KellyOCG + Sevenstep combines extensive industry experience with ongoing technology investments to deliver world-class programs tailored to unique workforce needs [5]

CGTN published an article on Peng Liyuan, wife of Chinese President Xi Jinping and UNESCO special envoy for the advancement of girls' and women's education, and UN Under-Secretary-General and UN Women Executive Director Sima Bahous, attending an exhibition showcasing China's progress in digital and intelligent empowerment for women and girls in Beijing. Through highlighting Peng's remarks at the event and introducing China's efforts to empower women and girls through technology, the article stresses the cou ...

Members See 46% Improvement in Work-Related Quality of Life and 53% Improvement in Overall Quality of Life WeightWatchers Members Lost 21% of Their Body Weight, Outperforming Results by Other Telehealth Providers NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers” or the “Company”), the global leader in science-backed weight management, today published its 2025 Annual Report from WeightWatchers for Business, offering a comprehensive, data-driven view of how its ...

SWISS-OWNED ICONS OF AUTOMOBILE HISTORY INCLUDES A 1966 FERRARI 275 GTB ALLOY WITH CONTINUED SWISS OWNERSHIP HISTORY | EXTREMELY DESIRABLE 1956 JAGUAR D-TYPE SHORT-NOSE THAT HAS BEEN WELL PRESERVED AND WIDELY ACKNOWLEDGED TO BE ONE OF THE MOST ORIGINAL IN EXISTENCE | AUCTION TAKES PLACE ON 1 NOVEMBER 2025 AT THE DOLDER GRAND HOTEL IN ASSOCIATION WITH AUTO ZÜRICH Photo courtesy of Broad Arrow Auctions 2024 Aston Martin Valkerie Spider Photo courtesy of Broad Arrow Auctions 1954 Jaguar D-Type Biceste ...

TORONTO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- White Gold Corp. (TSX.V: WGO, OTCQX: WHGOF, FRA: 29W) (the “Company” or “White Gold”) is pleased to announce it has closed its previously announced brokered private placement consisting of the sale of units (the “Units”), premium flow-through units (the “FT Units”) and common shares issued as “flow-through shares” (the “FT Shares”, and together with the Units and FT Units, the “Offered Securities”), for aggregate gross proceeds of approximately $23 million, which i ...

Core Points - Osisko Development Corp. has increased its "bought deal" financing from C$60 million to C$75 million due to excess demand [1] - The financing includes three tranches of shares under the "listed issuer financing exemption" for gross proceeds of approximately C$50 million and an additional private placement for approximately C$10 million [2] - The Concurrent Private Placement has been increased by approximately C$15 million, totaling 5,230,200 Common Shares at a price of C$4.78 per share for gross proceeds of C$25,000,356 [3] - The closing of both the LIFE Offering and the Concurrent Private Placement is expected on or about October 29, 2025, subject to regulatory approvals [4] Company Overview - Osisko Development Corp. is focused on gold development in North America, aiming to become an intermediate gold producer by advancing its Cariboo Gold Project in British Columbia [6] - The company also has projects in Utah and Mexico, emphasizing long-life, socially and environmentally responsible mining assets while minimizing development risk [6]

Core Viewpoint - Osisko Development Corp. has increased its previously announced "bought deal" financing from C$60 million to C$75 million due to excess demand [1][2]. Group 1: Offering Details - The offering consists of three tranches of shares under the "listed issuer financing exemption," aiming for gross proceeds of approximately C$50 million, along with an additional private placement for approximately C$10 million [2]. - Following an amendment, the size of the Concurrent Private Placement has been increased by approximately C$15 million, resulting in a total of 5,230,200 Common Shares at a price of C$4.78 per share, yielding gross proceeds of C$25,000,356 [3]. - The closing of both the LIFE Offering and the Concurrent Private Placement is expected on or about October 29, 2025, subject to regulatory approvals [4]. Group 2: Company Overview - Osisko Development Corp. is focused on developing gold mining projects in North America, particularly the Cariboo Gold Project in British Columbia, with additional projects in Utah and Mexico [6]. - The company's strategy emphasizes the development of long-life, socially and environmentally responsible mining assets while minimizing development risks [6].

Tools like Sezzle Up, Price Comparison, and Delivery Protection help shoppers buy responsibly while boosting conversion and loyalty for merchantsMinneapolis, MN, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Sezzle Inc. (NASDAQ:SEZL) (Sezzle or Company) // Sezzle, a leading buy now, pay later (BNPL) platform, today shared how it is helping retailers capture more shoppers for Black Friday, Cyber Monday, and the 2025 holiday season. According to a Sezzle survey conducted in July 2025, nearly half of surveyed Sezzle shopp ...

Core Insights - EHang Holdings Limited has launched an Advanced Air Mobility (AAM) Sandbox Initiative in Thailand, aiming to fast-track commercial operations of its EH216-S pilotless eVTOL aircraft [1][5] - The Initiative is a collaboration with the Civil Aviation Authority of Thailand (CAAT) and local partners, focusing on establishing the world's first commercial eVTOL operations through an innovative regulatory "sandbox" approach [1][6] - Continuous trial operations of the EH216-S have commenced in Bangkok, with plans to expand to additional locations across Thailand [1][6] Company Developments - The EH216-S successfully completed a series of autonomous flights during the launch event, demonstrating its flight control systems and operational reliability [3][5] - EHang held a technical meeting with CAAT officials to present the EH216-S's safety architecture and risk assessment framework, which is crucial for gaining local regulatory approval [5][9] - Local partners will provide operational support, including infrastructure and teams, to expand the sandbox areas for sightseeing and transportation services [6][10] Industry Context - Thailand is positioned as a strategically vital AAM market due to its strong service sector, tourism industry, and government policies promoting smart transportation [8][10] - The country's urban areas, particularly Bangkok, face traffic congestion, making it an ideal environment for AAM solutions [8][10] - The CAAT and Ministry of Transport (MOT) of Thailand are committed to advancing sustainable transportation and positioning Thailand as a regional AAM hub [9][10]

Sonnet BioTherapeutics is an oncology-focused biotechnology company with a proprietary platform for developing targeted biologic drugs with single or bifunctional action. Known as FHAB (Fully Human Albumin- Binding), the Company's technology utilizes a fully human single chain antibody fragment (scFv) that binds to and "hitch-hikes" on human serum albumin (HSA) for transport to the TME. Sonnet's FHAB was designed to specifically target tumor and lymphatic tissue, with an improved therapeutic window for opti ...